

Maria Jesus Perugorria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6049758/publications.pdf>

Version: 2024-02-01

43
papers

4,352
citations

257450

24
h-index

254184

43
g-index

43
all docs

43
docs citations

43
times ranked

5550
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. <i>Hepatology</i> , 2022, 76, 1617-1633.	7.3	15
2	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	3.7	11
3	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 585-604.	17.8	15
4	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. <i>Journal of Hepatology</i> , 2022, 77, 991-1004.	3.7	22
5	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. <i>Hepatology</i> , 2021, 73, 186-203.	7.3	7
6	Pathogenesis of Cholangiocarcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 433-463.	22.4	63
7	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. <i>Journal of Hepatology</i> , 2021, 74, 394-406.	3.7	14
8	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021, 70, 1345-1361.	12.1	59
9	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , 2021, 81, 2874-2887.	0.9	27
10	Inhibition of NAE1-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 848-859.	3.8	7
11	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. <i>Journal of Hepatology</i> , 2021, 75, 363-376.	3.7	29
12	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020, 40, 1670-1685.	3.9	22
13	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020, 9, 721.	4.1	63
14	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
15	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 497-511.	17.8	73
16	The tumour microenvironment and immune milieu of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 63-78.	3.9	109
17	Wnt β -catenin signalling in liver development, health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 121-136.	17.8	341
18	Cholangiocyte-Hepatocyte Differentiation: A Context-Dependent Process and an Opportunity for Regenerative Medicine. <i>Hepatology</i> , 2019, 69, 480-483.	7.3	6

#	ARTICLE	IF	CITATIONS
19	Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. <i>Cut</i> , 2019, 68, 533-546.	12.1	96
20	MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. <i>Hepatology</i> , 2018, 68, 561-573.	7.3	54
21	Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients. <i>Hepatology</i> , 2018, 68, 811-814.	7.3	4
22	MicroRNAâ€506 promotes primary biliary cholangitisâ€like features in cholangiocytes and immune activation. <i>Hepatology</i> , 2018, 67, 1420-1440.	7.3	72
23	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1468-1477.	3.8	72
24	Extracellular Vesicles in Hepatobiliary Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 2270.	4.8	29
25	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. <i>Journal of Hepatology</i> , 2018, 69, 1371-1383.	3.7	35
26	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 72-83.	3.7	81
27	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. <i>Digestive Diseases</i> , 2017, 35, 275-281.	1.9	8
28	O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC. <i>Journal of Hepatology</i> , 2017, 67, 218-220.	3.7	3
29	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017, 66, 1125-1143.	7.3	218
30	Novel causative genes for polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 391-392.	17.8	15
31	Effect of pravastatin on the survival of patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 4379-4384.	1.8	15
32	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1838-1846.	1.2	60
33	Elevated interleukinâ€8 in bile of patients with primary sclerosing cholangitis. <i>Liver International</i> , 2016, 36, 1370-1377.	3.9	34
34	TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury. <i>Journal of Immunology</i> , 2016, 196, 4298-4310.	0.8	16
35	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	17.8	964
36	More insight into the diversity of cholangiocyte ciliopathies. <i>Journal of Hepatology</i> , 2016, 65, 1083-1085.	3.7	1

#	ARTICLE	IF	CITATIONS
37	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 15-27.	1.5	20
38	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. <i>Journal of Hepatology</i> , 2015, 63, 952-961.	3.7	56
39	Polycystic liver diseases: advanced insights into the molecular mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 750-761.	17.8	80
40	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. <i>Gut</i> , 2014, 63, 1658-1667.	12.1	55
41	Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. <i>Hepatology</i> , 2013, 57, 1238-1249.	7.3	41
42	Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. <i>Hepatology</i> , 2012, 56, 1129-1139.	7.3	108
43	Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. <i>Nature Medicine</i> , 2011, 17, 1668-1673.	30.7	177